Genedrive Stock
Genedrive Plc
Company data
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Country
- United Kingdom
- CEO
- Gino Miele
- Employees
- 43
- Market cap
- £17 M
- IPO
- 04/04/2007
Genedrive Plc, a molecular diagnostics firm established in Manchester, UK, in 2000 (and known as Epistem Holdings Plc until its name change in July 2016), focuses on developing and commercializing innovative point-of-care diagnostic platforms. These solutions cater to a range of applications, including the…
Genedrive stock: price history
1D
-4.5%
1W
-8.7%
1M
-16.0%
6M
+10.5%
YTD
+21.4%
1Y
+83.2%
2Y
-61.4%
5Y
-94.1%
10Y
-97.9%
Next earnings date
Next earnings date
24/11/2026 (in 38 days)
Volatility around earnings
~206% stronger price swings than usual
Ask the agents about Genedrive
Genedrive stock metrics
P/E
-0.96
P/B
-21.41
EV/EBITDA
-3.04
RETURN ON EQUITY
588.2%
NET MARGIN
-527.2%
DEBT/EQUITY
-1.2
DIVIDEND YIELD
0.0%
AS OF
31/12/2025
Free float & liquidity
FREE FLOAT
46.4%
FLOAT SHARES
745,705,381
AVG. DAILY VOLUME (30D)
3,499,362
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Genedrive stock
What does Genedrive do?
Genedrive Plc is a company in the Healthcare sector, Medical - Diagnostics & Research industry, headquartered in United Kingdom.
The CEO is Gino Miele, the company employs around 43 people.
The IPO was on 04/04/2007; the stock trades on LSE under the ticker GDR.L.
When does Genedrive report next?
The next earnings date is 24/11/2026.
Around past earnings, price swings were roughly 206% stronger than usual.
Does Genedrive pay a dividend?
No, Genedrive currently does not pay a dividend.
Which stocks are comparable to Genedrive?
Comparable stocks include Thermo Fisher Scientific, Danaher, Natera, Agilent Technologies, IQVIA Holdings, Waters, Illumina and IDEXX Laboratories.
How can I get Genedrive stock analyzed?
Clicking "Analyze stock" lets five strategies assess Genedrive against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.